The Luvmeebody Wellnessclub/Blogs/Articles

For years, GLP-1 receptor agonists have been central to conversations about blood sugar control and, more recently, weight management. These medications, which mimic a natural gut hormone, have been a significant tool in metabolic medicine [4]. Now, compelling new evidence is expanding their role into one of the most critical areas of wellness: cardiovascular protection.

A recent, large-scale study has provided powerful data showing that these medications can do more than manage weight and glucose—they can also shield the heart. This development marks a pivotal moment, shifting our understanding of how we can proactively address cardiovascular risk in certain populations.

What the Research Shows

The key evidence comes from the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) clinical trial, a large, randomized, placebo-controlled study published in The New England Journal of Medicine [1]. This multi-year study involved over 17,600 adults from 41 countries who had pre-existing cardiovascular disease and a BMI indicating overweight or obesity, but who did not have diabetes [1].

In this landmark trial, participants receiving a weekly 2.4 mg injection of semaglutide (the active ingredient in Wegovy) saw a 20% lower risk of experiencing a major adverse cardiovascular event—defined as a nonfatal heart attack, a nonfatal stroke, or death from cardiovascular causes—compared to those receiving a placebo [1]. This protective effect was observed over an average follow-up period of about 40 months and appeared to be more significant than what could be attributed to weight loss alone, suggesting other beneficial mechanisms may be at play, such as reducing inflammation [3, 6].

Based on these robust findings, the U.S. Food and Drug Administration (FDA) took a significant step in March 2024. The agency officially expanded the approved use of Wegovy (semaglutide) to include the reduction of risk for major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [2]. This was the first time a weight-loss medication has been approved for this secondary prevention purpose.

GLP-1 agonists work by mimicking the hormone glucagon-like peptide-1, which helps regulate appetite and blood sugar [4]. The cardiovascular benefits are thought to arise from a combination of factors, including weight loss, improved blood pressure, better lipid profiles, and potential direct anti-inflammatory effects on the cardiovascular system [1, 5].

What This Means for Everyday Wellness

This new FDA indication is a paradigm shift. It formally recognizes the treatment of obesity as a strategy for preventing cardiovascular events like heart attack and stroke in high-risk individuals [2, 5]. It reinforces the deep, biological link between carrying excess weight and the health of our heart and blood vessels.

However, it’s crucial to understand the specifics of this approval. This indication is not for general weight loss or for anyone seeking to prevent heart disease. It is specifically for adults who already have cardiovascular disease and also live with obesity or overweight [2]. It is intended as a tool for secondary prevention—that is, to reduce the risk of a future event in someone who has already had one.

These medications are an addition to, not a replacement for, other foundational pillars of heart health. Participants in the SELECT trial continued to receive standard care for their conditions, including medications to manage blood pressure and cholesterol [1]. A heart-healthy lifestyle, including a balanced diet, regular physical activity, and not smoking, remains the cornerstone of cardiovascular wellness.

Like all medications, GLP-1 agonists have potential side effects. The most common are gastrointestinal, including nausea, diarrhea, vomiting, and constipation, which were reported in the SELECT trial [1, 6]. Any decision to start, stop, or change a medication should be a collaborative one made with a healthcare provider who can assess your individual health profile, risks, and potential benefits.

A Gentle Reminder

This development is a significant advance in our ability to treat metabolic and cardiovascular health as the interconnected systems they are. As the science evolves, your care should always be guided by a personalized conversation with your trusted medical team.

Sources and Resources

1. [1] The New England Journal of Medicine. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023-11-11). https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
2. [2] U.S. Food and Drug Administration (FDA). FDA Approves First Treatment to Reduce Risk of Heart Attack, Stroke and Cardiovascular Death in Adults With Cardiovascular Disease and Either Obesity or Overweight (2024-03-08). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-heart-attack-stroke-and-cardiovascular-death-adults
3. [3] Harvard Health Publishing. Wegovy approved to treat more than obesity (2024-04-22). https://www.health.harvard.edu/blog/wegovy-approved-to-treat-more-than-obesity-202404223030
4. [4] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). GLP-1 Agonists (2024). https://www.niddk.nih.gov/health-information/diabetes/overview/managing-diabetes/glp-1-agonists
5. [5] Centers for Disease Control and Prevention (CDC). Obesity and Cardiovascular Disease (2024-07-23). https://www.cdc.gov/obesity/data/obesity-and-cardiovascular-disease.html
6. [6] Mayo Clinic. Landmark study finds weekly injection of semaglutide reduces risk of heart attack, stroke in people with obesity (2023-11). https://www.mayoclinic.org/medical-professionals/cardiovascular-diseases/news/landmark-study-finds-weekly-injection-of-semaglutide-reduces-risk-of-heart-attack-stroke-in-people-with-obesity/mac-20549429

---

Educational disclaimer: This article is for general wellness education only. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. It is not a substitute for consultation with a qualified healthcare professional. Always speak with your clinician before starting or changing any medication, supplement, or wellness routine, especially if you are pregnant, nursing, taking medication, or managing a health condition.

---

Explore more guided wellness at
The Luvmee Body Wellness Club.

---